ClinicalTrials.gg
CompletedNCT07934368VR during CathUpdated Nov 13, 2026

The Effect of Virtual Reality Distraction on Anxiety, Pain, and Satisfaction in Patients Undergoing Cardiac Catheterization in Palestine

An interventional study of Virtual Reality Distraction and Standard peri-procedural Care in Anxiety, Pain and Satisfaction, sponsored by Arab American University (Palestine). Completed at 1 site in Palestinian Territories. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionPainRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Arab American University (Palestine) · Not applicable, Interventional, and Supportive care

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial evaluated the effect of immersive virtual reality (VR) distraction on procedural anxiety, pain, and patient satisfaction among adult patients undergoing cardiac catheterization.

Patients undergoing cardiac catheterization often experience significant anxiety and pain, which can negatively affect procedural outcomes and overall patient satisfaction. Immersive virtual reality has emerged as a promising non-pharmacological nursing intervention to mitigate procedural distress.

Participants were randomized into two groups: an intervention group receiving immersive VR distraction prior to and during the catheterization procedure, and a control group receiving standard nursing care. Procedural anxiety, pain intensity, and overall satisfaction were assessed using validated measurement instruments to determine the efficacy of the intervention.

Read the detailed description

Background:

Cardiac catheterization is a widely performed invasive diagnostic and therapeutic procedure. Despite its clinical safety, patients frequently experience high levels of pre-procedural and intra-procedural anxiety and physical pain, which can induce hemodynamic instability and reduce patient satisfaction.

Study Design and Setting:

This study was conducted as a single-center, parallel-group, randomized controlled clinical trial at An-Najah National University Hospital in Nablus, Palestine.

Methods \& Procedure:

A total of 92 eligible adult patients scheduled for cardiac catheterization were enrolled and randomly allocated (1:1) to either:

  1. VR Intervention Group: Received immersive virtual reality distraction (using a head-mounted display presenting relaxing virtual environments) delivered before and during the catheterization procedure alongside standard care.
  2. Control Group: Received standard peri-procedural nursing care.

Outcomes \& Measurements:

Primary Outcome: Procedural anxiety measured before and after the intervention using a validated anxiety scale. Procedural pain intensity measured via the Numeric Rating Scale (NRS) and overall patient satisfaction assessed post-procedure.

Ethical Considerations:

Ethical approval was granted by the Institutional Review Board at Arab American University (R-2026/A/82/N). All participants provided written informed consent prior to enrollment.

02

Conditions studied

  • Anxiety
  • Pain
  • Satisfaction
  • Cardiac Catheterizations

Browse trials for

Keywords

  • Virtual Reality
  • Distraction
  • Nursing Intervention
  • Randomized Controlled Trial
03

In context

Pain Reclassified

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

This study's enrollment of 92 is above the median of 66 across 8,505 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Arab American University (Palestine) is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Compared within Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years undergoing elective diagnostic or interventional cardiac catheterization.
  • Able to understand and provide consent in Arabic.
  • No to VR (e.g., severe motion sickness, uncontrolled epilepsy).

Exclusion criteria

Exclusion Criteria:

  • Emergency cardiac catheterization.
  • Cognitive impairments that might obstruct participation.
  • Severe visual or auditory impairments incompatible with VR use.
  • History of significant adverse reactions to VR.
  • Previous participation in a VR intervention study related to cardiac procedures
  • A documented history of an anxiety disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Active comparator
    Control Group

    Patients in this group received standard peri-procedural nursing and medical care before the cardiac catheterization procedure without virtual reality distraction.

    Other: Standard peri-procedural Care

  • Experimental
    VR Intervention Group

    VR Intervention Group patients in this group received immersive virtual reality (VR) distraction using a head-mounted display presenting relaxing virtual environments before the cardiac catheterization procedure, alongside standard care.

    Device: Virtual Reality Distraction

Interventions

  • DeviceVirtual Reality Distraction

    Experimental VR Intervention Group Patients in this group received immersive virtual reality (VR) distraction using a head-mounted display presenting relaxing virtual environments before the cardiac catheterization procedure, alongside standard care.

  • OtherStandard peri-procedural Care

    Standard clinical and nursing care during cardiac catheterization without virtual reality intervention.

06

What researchers measure

Primary outcomes

  1. State Anxiety Measured by the State-Trait Anxiety Inventory, State Anxiety Subscale (Form Y-1)

    State anxiety was measured using the Arabic version of the State-Trait Anxiety Inventory, State Anxiety Subscale (Form Y-1), a 20-item self-report questionnaire. Total scores range from 20 (minimum) to 80 (maximum); higher scores indicate greater anxiety (a worse outcome). The between-group difference in change from baseline was assessed at the pre-procedural assessment (immediately after the 15-minute virtual reality session in the intervention group, or after an equivalent routine waiting period in the control group) and at the post-procedural assessment.

    Time frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

  2. Pain Intensity Measured by the Numeric Rating Scale

    Pain intensity was measured using an 11-point Numeric Rating Scale. Scores range from 0 (no pain, minimum) to 10 (worst possible pain, maximum); higher scores indicate greater pain intensity (a worse outcome).

    Time frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

  3. Satisfaction With Nursing Care Measured by the Patient Satisfaction With Nursing Care Quality Questionnaire

    Satisfaction with nursing care was measured using the Arabic version of the Patient Satisfaction With Nursing Care Quality Questionnaire. Each of the 17 items is rated from 1 (poor) to 5 (excellent), and the score is the mean of the items, ranging from 1 (minimum) to 5 (maximum); higher scores indicate greater satisfaction (a better outcome).

    Time frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

07

Study locations

1 site
  • An-Najah National University Hospital (NNUH)
    Nablus, Nablus P400, Palestinian Territories
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared to protect patient privacy and confidentiality in accordance with the institutional review board approvals and informed consent agreements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Oct 2026, 1 month.

Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 13, 2026
StartActual
Sep 1, 2026
Primary completionActual
Oct 20, 2026
CompletionActual
Oct 20, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934368
Lead sponsor
Arab American University (Palestine)
Collaborators
Universidad Autonoma de Madrid, An-Najah National University
Responsible party
Murad Abdalkareem Husen Jkhlab (PhD Candidate, Arab American University (Palestine)) — Principal investigator
First posted
Nov 13, 2026
Start date
Sep 1, 2026
Primary completion
Oct 20, 2026
Completion
Oct 20, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion